Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

lopinavir-ritonavir

lopinavir-ritonavir
  • Restricted Severe/Confirmed COVID-19 or continuation of maitenance therapy.
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Kaletra SOLUTION, ORAL 20-80 mg/mL      
Kaletra TABLET, ORAL 100 mg-25 mg      
Kaletra TABLET, ORAL 200 mg-50 mg    
VIEW MORE HIV Protease Inhibitors
CLASS
08180808
Comments:

Formulary, Restricted to severe/confirmed COVID-19 infection by infectious disease/critical care prescribers or continuation of maintenance therapy.

Automatic stop date of 14 days (28 doses) for COVID-19 infection.  Continuation beyond 14 days must be approved by ID specialist.  Any new order should also have an automatic 14 day stop date

Encourage inpatients on maintenance therapy for HIV to utilize home supply if available.

 

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

lopinavir-ritonavir (Kaletra)

  • 200 mg-50 mg tablet oral

lopinavir-ritonavir (Kaletra)

  • TWO 100 mg-25 mg tablets (Total: 200 mg-50 mg)

 

Kaletra capsules medication guide

Kaletra tablets and solution medication guide

 

Updated: March 20, 2020 (COVID-19)

Last updated: Nov. 16, 2022






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved